{"url_path":"/sec/kapa/10-q/2026/item-1a","section_key":"item-1a","section_title":"Item 1A Risk Factors**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1962011/0001493152-26-022796-index.html","accession_number":"0001493152-26-022796","cik":"0001962011","ticker":"KAPA","issuer_name":"Kairos Pharma, LTD.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1962011/0001493152-26-022796-index.html","primary_entity_key":"0001962011","primary_entity_name":"Kairos Pharma, LTD."},"word_count":148,"has_tables":true,"body_markdown":"**Item\n1A. Risk Factors**\n\n \n\nAs\na smaller reporting company, we are not required to provide the information required by this item. You should carefully consider the\nfactors discussed in “Part I, Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025,\nwhich could materially affect our business, financial condition or future results. We may be unable for many reasons, including those\nthat are beyond our control, to implement our business strategy successfully. The occurrence of any single risk or any combination of\nrisks could materially and adversely affect our business, financial condition, results of operations, cash flows and the trading price\nof our common stock. As of the date of this report there has been no material change in any of the risk factors described in our Annual\nReport on Form 10-K for the fiscal year ended December 31, 2025."}